Long-Term Safety and Efficacy Data of a Plasma-Derived Factor VIII Concentrate with von Willebrand Factor for Treatment of Patients with Hemophilia A Covering 18 Years
Kittler, S.-F.-K.; Miesbach, W.; Bauhofer, A.; Becker, T.; Schüttrumpf, J.; Dubovy, P.; Nemes, L.; Richter, H.; Königs, C. · Zeitschrift für Orthopädie und Unfallchirurgie · 2019 · Heft 04 · S. 360 bis 367
Bibliografische Angaben
Zusammenfassung
AbstractWe describe the results of the (to our knowledge) longest long-term noninterventional study so far performed to obtain real-life data on the treatment of hemophilia A patients with a single plasma-derived FVIII concentrate containing von Willebrand factor (pdFVIII; Haemoctin/Faktor VIII SDH Intersero). A total of 198 patients (146 in Germany and 52 in Hungary), of whom 160 had severe and 38 nonsevere hemophilia A, representing all age groups (0–88 years; mean ∼25 years at inclusion) were analyzed during prophylactic or on-demand treatment over 18 years (overall 1,418 patient-years; mean >7 years). pdFVII…
